NEW YORK and BERLIN, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in ...

Summary: Investigators demonstrated that an experimental compound called BA-101 can successfully strip away glioblastoma’s defensive armor. By selectively blocking an enzyme that fuels the tumor’s ...

— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC ...

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of ...

Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine). Last patient expected to be dosed this week, with the total ...

– ALTO-101 demonstrated a favorable pharmacokinetic and tolerability profile; novel transdermal formulation delivered significantly greater drug exposure and fewer adverse events typically associated ...

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric ...

– ALTO-101 has been shown to positively impact cognition and key cognition-related EEG markers in humans when delivered orally – – Novel transdermal formulation of ALTO-101 exhibited favorable ...